Eliem Therapeutics
Eliem Therapeutics develops drug candidates for nervous system disorders, including chronic pain, mood disorders and epilepsy. It aims to provide new treatment options for people affected by these conditions.
Facts
- HQ
- Redmond, WA, US
- Sectors
- Biotech, Pharmaceuticals, Healthcare
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Skytap raises $12M Series E, bringing total disclosed funding to $110M; investors include Vistara Growth and Goldman Sachs
Skytap, a Seattle-based company led by CEO Brad Schick, has raised $110M in total disclosed funding, most recently a $12M Series E round in August 2021 backed by investors including Vistara Growth, Goldman Sachs, and Insight Venture Partners.
Remitly files S-1 ahead of IPO after 2020 revenue doubles to $257M and $1.5B valuation
Remitly filed an S-1 ahead of a conventional IPO, reporting $257M revenue and a $32.5M net loss for 2020 and $202M revenue with a $9.2M loss in H1 of the current year, with a $1.5B valuation from a July funding round and roughly $16.1B in trailing 12-month send volume.
Eliem Therapeutics raises $80M in IPO, prices 6.4M shares at $12.50 and lists on Nasdaq as ELYM
Eliem Therapeutics priced 6.4 million shares at $12.50 in an IPO that raised $80 million and will trade on Nasdaq as ELYM, with shares closing at $15.90 (up 27%). The Redmond biotech, founded ~3 years ago and led by Bob Azelby, is early-stage with no product revenue, a $46.7M deficit, 25 employees, and is developing CNS-focused therapies for pain, psychiatry and epilepsy.
See all 6 stories, episodes and videos about Eliem Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events